NxStage(R) Announces New Vice President and General Manager, Critical Care Therapies
LAWRENCE, Mass., Feb 23, 2010 /PRNewswire via COMTEX/ — NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Elise A. Tordella has joined the Company as Vice President and General Manager of Critical Care Therapies. In this position, Ms. Tordella will oversee NxStage’s strategic growth initiatives to provide quality continuous renal replacement therapy (CRRT) solutions to the estimated U.S. $100 million critical care market opportunity.
In addition to pioneering the home dialysis market with the System One, NxStage is an established leader in the critical care market, achieving an estimated 25 percent U.S. market share, said Joseph E. Turk, Senior Vice President, Commercial Operations, NxStage Medical. The critical care market is a strategic component to our overall growth and profitability. We are delighted to have Elise Tordella on board. Her wealth of experience in sales and marketing for the medical device industry globally will drive efforts to deepen our penetration in the critical care dialysis market.
I am excited to join NxStage and be a part of a company that is making significant contributions to the dialysis community, specifically critical care patients, said Elise Tordella. I look forward to using my knowledge and experience in the medical device industry to help foster NxStage’s continued growth in the critical care market and further enhance our value proposition to customers.
Tordella brings to NxStage more than 25 years of experience in multiple segments of the medical device industry, including renal, cardiology and general hospital products. Most recently, Tordella served as the Vice President of Global Marketing for Patient Care at Covidien, a company that manufactures, distributes and services medical devices, pharmaceuticals and medical supplies. Additionally, in her 18 year career at Covidien, Tordella was U.S. President for the Ludlow Division and has held a variety of marketing, product development and general management positions with the company.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of End Stage Renal Disease (ESRD) and acute kidney failure. For more information on NxStage and its products, please visit NxStage’s website at https://www.nxstage.com/.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words anticipate, believe, expect, estimate, plan, and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage’s filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2009. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact
Kristen Sheppard
NxStage Medical, Inc.
ir@nxstage.com
978-332-5923
Media Contact
Jane Hauser or Jasmine Fielding
Schwartz Communications, Inc.
nxstage@schwartz-pr.com
781-684-0770
SOURCE NxStage Medical, Inc.
